KOE:214450
PharmaResearch Co., Ltd. · KOE · Healthcare · KRW · FY for 2025
Figures on this page computed 2026-11-08 10:09 UTC
Last close
n/aKRW
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
14.8xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
22.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
30.8%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
28.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.31Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.5%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales2.89x
Its own average over 10 years, 185.30B.
- Profit3.23x
Its own average over 10 years, 51.17B.
- Free cash flow4.06x
Its own average over 10 years, 37.83B.
- Debt3.65x
Its own average over 8 years, 58.53B.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 4.06 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 118.5 | 93.1 | 98.8 |
| 2018-12-31 | 139.9 | 103.6 | 103.4 |
| 2019-12-31 | 182.5 | 119.8 | 99.8 |
| 2020-12-31 | 236.6 | 235.6 | 100.5 |
| 2021-12-31 | 335.3 | 335.7 | 106.3 |
| 2022-12-31 | 423.8 | 291.7 | 105.4 |
| 2023-12-31 | 568.0 | 550.4 | 111.6 |
| 2024-12-31 | 761.9 | 661.8 | 111.6 |
| 2025-12-31 | 1,165.8 | 1,187.1 | 109.8 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Figures behind the shape
Growth
37.6%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate37.6%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
Five-year EPS growth rate35.8%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
One-year change in net income79.4%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
Returns on capital
22.7%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capital22.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity23.9%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets15.8%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
75.1%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin75.1%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin39.6%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin30.8%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin28.7%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
14.8xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings14.8x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
Price to book3.5x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA10.8x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio4.5x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.31safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity0.31
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio6.88
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage20.4x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score7.15
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
0.5%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yield0.5%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
Payout ratio6.9%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio13.4x
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.